Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: Dose modification for weight is not necessary

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5640-5645

  Pai, Manjunath P ^a   Lodise Jr , Thomas P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY SIZE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; HUMAN; INFLUENZA VIRUS A H1N1; MALE; OBESITY; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BODY MASS INDEX; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OSELTAMIVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81555200428     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00422-11     Document Type: Article

References (24)

1. Akaike, H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242. (Pubitemid 9228573)
2. Ariano, R. E., et al. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363.
3. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
4. Davies, B. E. 2010. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.J. Antimicrob. Chemother. 65(Suppl. 2):ii5-ii10.
5. Eisenberg, E. J., A. Bidgood, and K. C. Cundy. 1997. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob. Agents Chemother. 41:1949-1952. (Pubitemid 27383234)
6. Flegal, K. M., M. D. Carroll, C. L. Ogden, and L. R. Curtin. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
7. Fuhrman, C., et al. 2010. Severe hospitalised 2009 pandemic influenza A(H1N1) cases in France, 1 July-15 November 2009. Euro Surveill. 15:19463
8. Hanley, M. J., D. R. Abernethy, and D. J. Greenblatt. 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49:71-87.
9. He, G., J. Massarella, and P. Ward. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484. (Pubitemid 30032251)
10. Louie, J. K., et al. 2011. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin. Infect. Dis. 52:301-312.
11. Louriz, M., et al. 2010. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in an university hospital of Morocco. Int. Arch. Med. 3:26.
12. Pai, M. P. 2010. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv. Chronic Kidney Dis. 17:e53-e62.
13. Patel, A., and S. E. Gorman. 2009. Stockpiling antiviral drugs for the next influenza pandemic. Clin. Pharmacol. Ther. 86:241-243.
14. Rayner, C. R., C. Pascal, R. Gieschke, L. M. Boak, and E. N. Jonsson. 2008. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J. Clin. Pharmacol. 48:935-947.
15. Roche. 2008. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. Roche, Nutley, NJ.
16. Schumitzky, A. 1995. EM algorithms and two stage methods in pharmacokinetics population analysis, p. 145-160. In D. A. D'Argenio (ed.), Advanced methods of pharmacokinetic and pharmacodynamic systems analysis, vol. 2. Plenum Press, New York, NY.
17. Udy, A. A., J. A. Roberts, R. J. Boots, D. L. Paterson, and J. Lipman. 2010. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet. 49:1-16.
18. Vaillant, L., G. La Ruche, A. Tarantola, and P. Barboza. 2009. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 14:19309.
19. Walker, S. 1996. An EM algorithm for nonlinear random effects models. Biometrics 52:934-944. (Pubitemid 26296070)
20. WHO. 2011. BMI classification. World Health Organization. Geneva, Switzerland. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html.
21. WHO. 2009. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications /swineflu/h1n1-use-antivirals-20090820/en/index.html.
22. Widmer, N., et al. 2010. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin. Pharmacokinet. 49:741-765.
23. Yano, Y., S. L. Beal, and L. B. Sheiner. 2001. Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodynam. 28:171-192.
24. Yu, H., et al. 2011. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin. Infect. Dis. 52:457-465.